1. Home
  2. REE vs HOTH Comparison

REE vs HOTH Comparison

Compare REE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.84

Market Cap

22.4M

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
HOTH
Founded
2011
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.4M
18.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
REE
HOTH
Price
$0.84
$1.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.75
$4.50
AVG Volume (30 Days)
104.6K
249.4K
Earning Date
12-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$183,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.66
52 Week High
$11.72
$3.80

Technical Indicators

Market Signals
Indicator
REE
HOTH
Relative Strength Index (RSI) 46.88 44.77
Support Level $0.70 $1.13
Resistance Level $0.94 $1.27
Average True Range (ATR) 0.10 0.08
MACD 0.01 0.01
Stochastic Oscillator 48.09 66.58

Price Performance

Historical Comparison
REE
HOTH

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Share on Social Networks: